Coats Group (LSE:COA) is stitching together growth by combining steady market-share gains in its core thread Business with the contribution from its OrthoLite footwear acquisition. In interim results published on 28 July 2026, the FTSE 250 company reported first-half Revenue of $837 million, up 19% on a reported basis from $705 million, while adjusted EBIT rose 19% to $166 million.

The underlying picture was more measured. Organic revenue growth at constant exchange rates was 1%, achieved against what chief executive David Paja described as "prolonged industry de-stocking". The company kept its adjusted EBIT Margin at 19.8% and left full-year expectations unchanged.

In short, Coats is using acquisitions, cost discipline and new product areas to keep Earnings moving while its end markets remain soft. The board also lifted the Interim Dividend by 5% to 1.05 cents per share.

The World's Thread Specialist

Coats describes itself as "the world's leading industrial thread and footwear components manufacturer". It employs around 19,000 people worldwide and is headquartered in the UK.

The group supplies thread and components to apparel and footwear makers, and it has been building positions in adjacent markets. In the first half, the company said these target adjacencies contributed one percentage point to revenue growth. It also reported $297 million of revenue from 100% recycled thread, a measure of how far sustainability has become part of its commercial offer.

That mix of scale, specialist products and a growing footprint beyond traditional apparel is central to how Coats seeks to outperform its markets.

Inside the First-Half Numbers

By segment, Apparel delivered 1% organic growth, helped by portfolio share gains and strength in China's domestic market and in automotive. Footwear revenue was flat on an organic basis, but Coats pointed to significant acceleration in the second quarter. The company also highlighted strong growth in composite tape sold into energy markets.

OrthoLite revenue was lower year on year against a strong comparative period. Coats said temporary capacity challenges in Indonesia were being resolved.

Further down the income statement, adjusted Basic Earnings Per Share fell 6% to 4.4 cents from 4.7 cents, even as adjusted EBIT rose. Statutory profit before tax was $104.3 million. At constant exchange rates, revenue rose 18% and adjusted EBIT also grew 18%, showing that currency movements added only modestly to the reported figures. Free Cash Flow was $30 million, down from $38 million a year earlier.

OrthoLite: The Deal Behind the Growth

The jump in reported revenue largely reflects the OrthoLite acquisition, which completed on 29 October 2025. Coats said the deal had an initial Enterprise value of $770 million, with cash consideration of $581.7 million for the entire Share Capital and a total cash outflow of $829.3 million including $247.6 million of Debt settlement.

Integration appears to be on track. Coats said OrthoLite is delivering the expected $5 million of cost synergies in 2026, with at least $20 million of annualised cost synergies targeted by 2028. Sales synergies are expected to add more than $40 million of incremental annual revenue by 2030.

Those targets matter because the deal added debt. Net debt excluding Lease liabilities stood at $842 million at 30 June 2026, compared with $815 million at the end of 2025, and Leverage was 2.3 times EBITDA. Management said leverage remains on track to be 2.0 times or below by the end of 2026. Reaching that level would give the board more flexibility on capital returns and further bolt-on investment.

Cash, Costs and Capital Returns

Coats (LSE:COA) is leaning on self-help to protect earnings. It announced incremental cost actions targeting around $15 million of benefits in the second half, and said it still expects good year-on-year earnings growth for 2026.

Over the longer term, the company is targeting roughly $1 billion of cumulative free cash flow over five years. Its stated capital allocation priorities are investing in organic growth and supporting a progressive dividend. After that, Coats said it would deploy surplus capital, "including giving consideration to a share buyback". No buyback was disclosed in the interim report.

The 1.05-cent interim dividend goes ex-dividend on 15 October 2026, with a Record Date of 16 October and payment on 12 November 2026.

Risks on the Loom

Demand is the first risk. Coats expects "modest market declines" in the second half, and a longer period of de-stocking by brands and manufacturers could weigh on volumes even if Coats continues to win share.

Integration and balance-sheet risk sit alongside that. OrthoLite revenue fell in the first half and faced capacity issues in Indonesia, while leverage of 2.3 times is above the company's year-end target. Any slippage in synergies or cash generation would slow the path to lower debt.

Earnings per share are another watch point. The first-half fall in adjusted EPS, despite higher EBIT, shows that headline profit growth does not automatically translate into per-share gains. Free cash flow also dipped year on year.

Finally, Coats operates a global Manufacturing footprint serving international Supply chains, so it remains exposed to currency swings and to shifts in trade policy that affect where apparel and footwear are made.

What to Watch Next

The near-term milestones are clear. The interim dividend record date is 16 October 2026 and payment follows on 12 November. Full-year 2026 results are expected in early 2027, when investors will see whether leverage has fallen to 2.0 times or below as guided.

Management noted that low inventory levels across the industry could support an improvement in demand, so any sign of restocking would be significant. Progress on OrthoLite synergies, the recovery of its Indonesian capacity and further growth in adjacencies such as composite tape will also be closely followed.

Coats has shown it can hold margins and grow profit in a difficult market. For now, the balance between cash generation, deleveraging and Investment in growth adjacencies remains the key test for the business. Whether it can convert that resilience into stronger organic growth and per-share earnings will shape how the story develops through 2027.